Skip to main content

Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.

Publication ,  Journal Article
Ullah, N; Mansha, M; Casey, PJ
Published in: Curr Cancer Drug Targets
2016

The process of protein prenylation involves the covalent linkage of either farnesyl (15-carbon) or geranylgeranyl (20-carbon) isoprenoid lipds to conserved cysteine residues in the carboxyl-terminus of proteins. Protein geranylgeranyltransferase I (GGTase-I) is the enzyme that catalyzes the addition of the geranylgeranyl moiety from geranylgeranyl pyrophosphate to the target protein, which contains a Cterminal consensus sequence termed a CaaX motif. Geranylgeranylation is important to the function of a number of proteins, including the majority of Rho GTPases, G protein gamma subunits, and several other regulatory proteins. Studies over the past two decades have revealed that many of these proteins contribute to tumor development and metastasis. Blocking Rho GTPase activity through inhibition of GGTase-I in particular has been advanced as a potential strategy for disease therapy. This review will provide an overview of the CaaX prenyltransferases, the rationale for targeting GGTase-I in cancer in particular, and the current status of GGTase-I inhibitor (GGTI) development.

Duke Scholars

Published In

Curr Cancer Drug Targets

DOI

EISSN

1873-5576

Publication Date

2016

Volume

16

Issue

7

Start / End Page

563 / 571

Location

Netherlands

Related Subject Headings

  • Protein Prenylation
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Farnesyltranstransferase
  • Enzyme Inhibitors
  • Animals
  • Alkyl and Aryl Transferases
  • 3404 Medicinal and biomolecular chemistry
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ullah, N., Mansha, M., & Casey, P. J. (2016). Protein Geranylgeranyltransferase Type 1 as a Target in Cancer. Curr Cancer Drug Targets, 16(7), 563–571. https://doi.org/10.2174/1568009616666151203224603
Ullah, Nisar, Muhammad Mansha, and Patrick J. Casey. “Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.Curr Cancer Drug Targets 16, no. 7 (2016): 563–71. https://doi.org/10.2174/1568009616666151203224603.
Ullah N, Mansha M, Casey PJ. Protein Geranylgeranyltransferase Type 1 as a Target in Cancer. Curr Cancer Drug Targets. 2016;16(7):563–71.
Ullah, Nisar, et al. “Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.Curr Cancer Drug Targets, vol. 16, no. 7, 2016, pp. 563–71. Pubmed, doi:10.2174/1568009616666151203224603.
Ullah N, Mansha M, Casey PJ. Protein Geranylgeranyltransferase Type 1 as a Target in Cancer. Curr Cancer Drug Targets. 2016;16(7):563–571.

Published In

Curr Cancer Drug Targets

DOI

EISSN

1873-5576

Publication Date

2016

Volume

16

Issue

7

Start / End Page

563 / 571

Location

Netherlands

Related Subject Headings

  • Protein Prenylation
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Farnesyltranstransferase
  • Enzyme Inhibitors
  • Animals
  • Alkyl and Aryl Transferases
  • 3404 Medicinal and biomolecular chemistry
  • 3211 Oncology and carcinogenesis